These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28558767)

  • 1. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
    Ricci F; Guffanti F; Damia G; Broggini M
    Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab.
    Bizzaro F; Falcetta F; D'Agostini E; Decio A; Minoli L; Erba E; Alessandro Peccatori F; Scanziani E; Colombo N; Zucchetti M; Bani MR; Ubezio P; Giavazzi R
    Int J Cancer; 2018 Nov; 143(9):2187-2199. PubMed ID: 29752717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.
    Decio A; Cesca M; Bizzaro F; Porcu L; Bettolini R; Ubezio P; Taraboletti G; Belotti D; Giavazzi R
    Clin Exp Metastasis; 2015 Oct; 32(7):647-58. PubMed ID: 26185056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the JAK2/STAT3 pathway in ovarian cancer results in the loss of cancer stem cell-like characteristics and a reduced tumor burden.
    Abubaker K; Luwor RB; Zhu H; McNally O; Quinn MA; Burns CJ; Thompson EW; Findlay JK; Ahmed N
    BMC Cancer; 2014 May; 14():317. PubMed ID: 24886434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling Cytostatic and Cytotoxic Responses to New Treatment Regimens for Ovarian Cancer.
    Falcetta F; Bizzaro F; D'Agostini E; Bani MR; Giavazzi R; Ubezio P
    Cancer Res; 2017 Dec; 77(23):6759-6769. PubMed ID: 28951463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models.
    Ponte JF; Ab O; Lanieri L; Lee J; Coccia J; Bartle LM; Themeles M; Zhou Y; Pinkas J; Ruiz-Soto R
    Neoplasia; 2016 Dec; 18(12):775-784. PubMed ID: 27889646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-resistant recurrent ovarian cancer with long survival on bevacizumab and gemcitabine.
    Komiyama S; Kugimiya T; Takeya C; Takahashi R; Kubushiro K
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1330-1334. PubMed ID: 29767464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platinum-based chemotherapy and bevacizumab instigate the destruction of human ovarian cancers via different signaling pathways.
    Kingnate C; Charoenkwan K; Kumfu S; Apaijai N; Jaiwongkam T; Khunamornpong S; Chattipakorn N; Chattipakorn SC
    Biochem Pharmacol; 2021 Jun; 188():114587. PubMed ID: 33932471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL; Watson JM; Gehrig PA; Fowler WC; Haskill JS
    Cancer Res; 1999 May; 59(10):2425-32. PubMed ID: 10344753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
    PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line.
    Teng PN; Bateman NW; Wang G; Litzi T; Blanton BE; Hood BL; Conrads KA; Ao W; Oliver KE; Darcy KM; McGuire WP; Paz K; Sidransky D; Hamilton CA; Maxwell GL; Conrads TP
    Hum Cell; 2017 Jul; 30(3):226-236. PubMed ID: 28251557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noscapine Increases the Sensitivity of Drug-Resistant Ovarian Cancer Cell Line SKOV3/DDP to Cisplatin by Regulating Cell Cycle and Activating Apoptotic Pathways.
    Shen W; Liang B; Yin J; Li X; Cheng J
    Cell Biochem Biophys; 2015 May; 72(1):203-13. PubMed ID: 25510462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
    Oliva P; Decio A; Castiglioni V; Bassi A; Pesenti E; Cesca M; Scanziani E; Belotti D; Giavazzi R
    Br J Cancer; 2012 Jul; 107(2):360-9. PubMed ID: 22713663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral recombinant methioninase combined with paclitaxel arrests recalcitrant ovarian clear cell carcinoma growth in a patient-derived orthotopic xenograft (PDOX) nude-mouse model.
    Sugisawa N; Higuchi T; Han Q; Hozumi C; Yamamoto J; Tashiro Y; Nishino H; Kawaguchi K; Bouvet M; Murata T; Unno M; Hoffman RM
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):61-67. PubMed ID: 33768300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    Torres D; Hou X; Bale L; Heinzen EP; Maurer MJ; Zanfagnin V; Oberg AL; Conover C; Weroha SJ
    PLoS One; 2019; 14(11):e0224564. PubMed ID: 31751381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.